High-resolution mass spectrometry proteomics for the identification of candidate plasma protein biomarkers for chronic obstructive pulmonary disease

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Biomarkers

• Publication date

  2010-05-17

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.3109/13547501003789901PMID 20429838
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Morbidity and Mortality Weekly Report

  2012cited by this paper
• Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers.

  2009cited by this paper
• Proteomic technologies for prenatal diagnostics: advances and challenges ahead

  2009cited by this paper
• Alpha2-Antiplasmin Is a Critical Regulator of Angiotensin II–Mediated Vascular Remodeling

  2008cited by this paper
• Serum Proteomic Profiling of Lung Cancer in High-Risk Groups and Determination of Clinical Outcomes

  2008cited by this paper
• Autoantibodies in patients with chronic obstructive pulmonary disease.

  2008cited by this paper
• QTL detection with bidirectional and unidirectional selective genotyping: marker-based and trait-based analyses

  2008cited by this paper
• The intracellular renin–angiotensin system: implications in cardiovascular remodeling

  2008cited by this paper
• COPD as a Systemic Disease

  2008cited by this paper
• The metabolic syndrome, diabetes and lung dysfunction.

  2008cited by this paper
• National Emphysema Treatment Trial state of the art: genetics of emphysema.

  2008cited by this paper
• Polymorphisms in interleukin-1B and its receptor antagonist genes and the risk of chronic obstructive pulmonary disease in a Korean population: a case-control study.

  2008cited by this paper
• Biomarkers of Systemic Inflammation in Stable and Exacerbation Phases of COPD

  2008cited by this paper
• α2‐Antiplasmin and its deficiency: fibrinolysis out of balance

  2008cited by this paper
• The renin–angiotensin system and diabetes: An update

  2008cited by this paper
• Complex chronic comorbidities of COPD

  2008cited by this paper
• Systemic inflammation and COPD: the Framingham Heart Study.

  2008cited by this paper
• Biomarkers in COPD: time for a deep breath

  2007cited by this paper
• Complement levels and activity in the normal and LPS-injured lung.

  2007cited by this paper
• Framingham Heart Study genome-wide association: results for pulmonary function measures

  2007cited by this paper
• From COPD to chronic systemic inflammatory syndrome?

  2007cited by this paper
• Vascular functions of the plasminogen activation system.

  2007cited by this paper
• The role of complement in inflammatory diseases from behind the scenes into the spotlight.

  2007cited by this paper
• KEGG for linking genomes to life and the environment

  2007cited by this paper
• CHRONIC OBSTRUCTIVE PULMONARY DISEASE Profiling serum biomarkers in patients with COPD: associations with clinical parameters

  2007cited by this paper
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

  2007influential reference
• Plasma gelsolin is a marker and therapeutic agent in animal sepsis*

  2007cited by this paper
• Insulin Resistance and inflammation—A Further Systemic Complication of COPD

  2007cited by this paper
• Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry

  2007cited by this paper
• Systemic effects of smoking.

  2007cited by this paper
• [COPD as a systemic disease].

  2007cited by this paper
• A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo.

  2007cited by this paper
• Proteomic analysis of serum, plasma, and lymph for the identification of biomarkers

  2007cited by this paper
• Angiogenesis in chronic lung disease.

  2007cited by this paper
• Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity – a common inflammatory phenotype?

  2006cited by this paper
• Predictors of lung function and its decline in mild to moderate COPD in association with gender: results from the Euroscop study.

  2006cited by this paper
• Proteomics and heart disease: identifying biomarkers of clinical utility

  2006cited by this paper
• Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels

  2006cited by this paper
• Why does airway inflammation persist after the smoking stops?

  2006cited by this paper
• Quest for novel cardiovascular biomarkers by proteomic analysis.

  2005cited by this paper
• Comparison of alternative analytical techniques for the characterisation of the human serum proteome in HUPO Plasma Proteome Project

  2005cited by this paper
• Controlling false discoveries in candidate gene studies

  2005cited by this paper
• Thrombus formation in vivo.

  2005cited by this paper
• Overview of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly‐available database

  2005influential reference
• Controlling false discoveries in candidate gene studies

  2005cited by this paper
• From genomics to chemical genomics: new developments in KEGG

  2005cited by this paper
• The role of smoking in coagulation and thromboembolism in chronic obstructive pulmonary disease.

  2005cited by this paper
• Interleukin-1beta causes pulmonary inflammation, emphysema, and airway remodeling in the adult murine lung.

  2005cited by this paper
• The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.

  2004cited by this paper
• Pulmonary vascular involvement in chronic obstructive pulmonary disease

  2003cited by this paper
• Estimates of global mortality attributable to smoking in 2000.

  2003cited by this paper
• Statistical methods for identifying differentially expressed genes in DNA microarrays.

  2003cited by this paper
• Hypothesis: Does COPD have an autoimmune component?

  2003cited by this paper
• Statistical significance for genomewide studies

  2003cited by this paper
• Chronic obstructive pulmonary disease: molecular and cellularmechanisms

  2003cited by this paper
• Smoking and lung function of Lung Health Study participants after 11 years.

  2002cited by this paper
• Systemic effects in COPD.

  2002cited by this paper
• Cytokines in chronic obstructive pulmonary disease

  2001cited by this paper
• Angiotensinogen in essential hypertension: from genetics to nephrology.

  2001cited by this paper
• Association between alpha‐1‐antichymotrypsin polymorphism and susceptibility to chronic obstructive pulmonary disease

  2000cited by this paper
• Chronic obstructive pulmonary disease.

  2000cited by this paper
• KEGG: Kyoto Encyclopedia of Genes and Genomes

  2000cited by this paper
• Apolipoprotein AIV: a potent endogenous inhibitor of lipid oxidation.

  1998cited by this paper
• Systemic oxidative stress in asthma, COPD, and smokers.

  1996cited by this paper
• Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.

  1995cited by this paper
• Controlling the false discovery rate: a practical and powerful approach to multiple testing

  1995cited by this paper
• Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1

  1994cited by this paper
• The Lung Health Study. Baseline characteristics of randomized participants.

  1993cited by this paper
• Mis-sense mutation of α1-antichymotrypsin gene associated with chronic lung disease

  1992cited by this paper
• Mis-sense mutation of alpha 1-antichymotrypsin gene associated with chronic lung disease.

  1992cited by this paper
• Thrombosis in inherited deficiencies of antithrombin, protein C, and protein S.

  1987cited by this paper
• [Systemic effects of smoking].

  1984cited by this paper

• Distinct Plasma Proteome in Severe Pulmonary Hypertension Associated with Chronic Lung Disease.

  2025cites this paper
• Evaluation of common protein biomarkers involved in the pathogenesis of respiratory diseases with proteomic methods: A systematic review

  2023cites this paper
• Review of recent lung biomarkers of potential harm/effect for tobacco research

  2021cites this paper
• CORESTA Biomarkers Sub-Group Technical Report Review of Recent Lung Biomarkers of Potential Harm / Effect for Tobacco Research September 2020

  2020cites this paper
• New Validated Method for Quantification of Glycated Hemoglobin by LC-QToF-MS: Is HRMS able to quantify clinical samples?

  2020cites this paper
• Analysis of the Plasma Proteome in COPD: Novel Low Abundance Proteins Reflect the Severity of Lung Remodeling

  2014cites this paper
• Biomarker discovery in asthma and COPD by proteomic approaches

  2014cites this paper
• Gender differences in the bronchoalveolar lavage cell proteome of patients with chronic obstructive pulmonary disease.

  2013cites this paper
• Advances in proteomic techniques for biomarker discovery in COPD

  2011cites this paper
• The role of coagulation in chronic inflammatory disorders: a jack of all trades.

  2011cites this paper
• Significance of bioinformatics in research of chronic obstructive pulmonary disease

  2011cites this paper